News | July 02, 2024
Merck and Orion announce option providing Merck global exclusive rights to Opevesostat
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Laurus Labs receives EIR from USFDA for API facilities
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Renews GMP certifications for India and Malaysia sites
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Subscribe To Our Newsletter & Stay Updated
